Company Focus
Moderna
Latest Moderna News
Biotechnology
US mRNA specialist Moderna today announced Health Canada has approved mRESVIA (respiratory syncytial virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older. 8 November 2024
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious
diseases
Latest News & Features of interest to Moderna
Biotechnology
Research news last week included US biotech Amgen holding an R&D conference call outlining its ambitions and achievements in the area of rare diseases, including Tepezza and Krystexxa. Also, USA-based Viking Therapeutics released new Phase II data for its obesity hopeful VK2735. Regulatory news saw the US Food and Drug Administration (FDA) reject approval of Minerva Neurosciences’ roluperidone, issuing a complete response letter (CRL) noting a lack of efficacy evidence. Also, Franco-American firm Allecra Therapeutics received authorization from the FDA for its Exblifep for the treatment of complicated urinary tract infections (cUTIs). US pharma giant Pfizer last Thursday held an investor meeting to outline plans for its oncology business following the $43 billion acquisition of Seagen. 3 March 2024
Biotechnology
More positive data for Abrysvo (respiratory syncytial virus vaccine) will support Pfizer’s position in an important new market for products targeting RSV infections. 1 March 2024
Pharmaceutical
Russia is experiencing, shortage of a unique drug against repeated heart attacks - Effient (prasugrel) from the American pharma major Eli Lilly representative of the Russian Ministry of Health told the business newspaper Vedomosti, the Pharma Letter’s local correspondent reports. 1 March 2024
Biotechnology
Avidity Biosciences has announced an oversubscribed $400 million private placement, with the news sending the US RNA-focussed biotech firm’s shares up 21.8% to $18.58 by mid-morning. 29 February 2024
Pharmaceutical
Last month, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the refusal of the marketing authorization for Nezglyal (leriglitazone) following a re-examination of the filing. 29 February 2024
Biotechnology
Swiss biotech Idorsia closed down more than 9% at 2.59 francs today, on news of a deal for two of its assets. 28 February 2024
Pharmaceutical
USA-based rare disease Applied Therapeutics today announced that the US Food and Drug Administration (FDA) has accepted the filing of the New Drug Application (NDA) for govorestat (AT-007) for the treatment of classic galactosemia 28 February 2024
Biotechnology
San Diego, USA-based Janux Therapeutics has seen its share price triple after positive early data were announced for JANX007 and JANX008. 28 February 2024
Biotechnology
French immunotherapy company OSE Immunotherapeutics was trading more than 50% higher by late Wednesday. 28 February 2024
Biotechnology
Chinese oncology specialist BeiGene has ended its collaboration with privately-held Shoreline Biosciences. 27 February 2024
Latest In Brief for Moderna
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Latest Relevant Ones To Watch News
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration. 15 November 2024
5 November 2024
18 October 2024
24 September 2024
23 September 2024
16 September 2024
23 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze